Last $3.93 USD
Change Today -0.0003 / -0.01%
Volume 19.6K
ADMP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

adamis pharmaceuticals corp (ADMP) Snapshot

Open
$3.95
Previous Close
$3.93
Day High
$3.98
Day Low
$3.91
52 Week High
12/5/13 - $11.90
52 Week Low
08/15/14 - $2.62
Market Cap
41.5M
Average Volume 10 Days
62.1K
EPS TTM
$-8.03
Shares Outstanding
10.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADAMIS PHARMACEUTICALS CORP (ADMP)

Related News

No related news articles were found.

adamis pharmaceuticals corp (ADMP) Related Businessweek News

No Related Businessweek News Found

adamis pharmaceuticals corp (ADMP) Details

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company’s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for the treatment of prostate cancer. The company is headquartered in San Diego, California.

adamis pharmaceuticals corp (ADMP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.2K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $247.7K
Vice President of Operations
Total Annual Compensation: $225.0K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $287.7K
Compensation as of Fiscal Year 2014.

adamis pharmaceuticals corp (ADMP) Key Developments

Adamis Pharmaceuticals Corporation Announces Executive Appointments

Adamis Pharmaceuticals Corporation announced additions to its medical and product marketing management teams. Dragana Males, M.D. has joined Adamis as a Medical Director. In this role, she will work closely with other senior management members to oversee all aspects of clinical development. Most recently, she served as Drug Safety Physician within the Medical Services Group of Product Safety and Risk Management at Mylan Inc. Jennifer C. Suski has joined Adamis as Senior Director of Marketing. Most recently, she was Director of Marketing for Santarus Inc. Joshua D. Seno has also joined Adamis from Santarus as Senior Director of Commercial Affairs bringing over 12 years of commercial experience with him. In his last role, was Director of Market Research & Forecasting for Santarus Inc.

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 06, 2014

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 06, 2014., at 10:00 Pacific Daylight. Location: 11682 El Camino Real, Suite 300. Agenda: To elect five directors to the Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified; to approve amendments to the company’s 2009 Equity Incentive Plan to increase by 1,000,000 shares the number of shares authorized for issuance there under, and to make certain other changes to the Plan as described in more detail in the Proxy Statement; to approve, on a nonbinding advisory basis, the compensation of the named executive officers; to ratify the selection of Mayer Hoffman McCann PC as the independent registered public accounting firm for the year ending March 31, 2015; and to transact such other business as may properly come before the Meeting or any adjournments or postponements thereof.

Adamis Pharmaceuticals Corporation Announces Board Changes

Adamis Pharmaceuticals Corporation announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Mr. Rothermel currently serves as a board member and chairman of the audit committee of Medcor and has also served as a board member of Cerescan. William C. Denby: From 2002-2014, Mr. Denby was Senior Vice President, Commercial Operations at Santarus Inc. which was acquired by Salix in January of 2014. These three new independent board members have replaced Tina S. Nova, Ph.D., Craig A. Johnson and Kenneth M. Cohen, who resigned from the Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMP:US $3.93 USD -0.0003

ADMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Delcath Systems Inc $1.43 USD +0.02
View Industry Companies
 

Industry Analysis

ADMP

Industry Average

Valuation ADMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMIS PHARMACEUTICALS CORP, please visit www.adamispharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.